Asia Dengue Voice and Action (ADVA) is a scientific working group dedicated to dengue vaccine advocacy in Asia, with the aim of disseminating information and making recommendations on dengue vaccine introduction strategies in Asia.
The group has formulated recommendations with an ultimate aim of translating the science of dengue vaccination into messages for policy makers, general public and health care workers.
The aim of this website is to help ADVA members identify opportunities and make practical recommendations for improving surveillance and laboratory capacity for dengue disease confirmation, including:
- documenting and standardising existing systems and coverage
- standardising case confirmation and diagnostics
- selecting initial target groups for vaccination
- addressing programme feasibility by improving existing infrastructure (cold chain, pharmacovigilance, vaccination compliance monitoring, and vaccine supply and distribution logistics)
- preparing and implementing a risk management plan
- collaborating with other relevant dengue initiatives including V2V (vaccine to vaccination) and the Dengue Vaccine Initiative
An Evolving Mission
At inception, ADVA, in both its title and focus stood for Asia Dengue Vaccination Advocacy. This has evolved to take on a broader remit in not only representing the Voice of Dengue in Asia, but also committing itself to Action.
This shift of focus to voice and action underpins the evolved definition of ADVA: Asia Dengue Voice and Action.
With input from government, public health entities, academia, the clinical community, consumer health organisations and industry bodies, ADVA has taken up the challenge of consulting and developing a regional blueprint for dengue management.
This blueprint will provide a cohesive, central and actionable point of view on dengue management across Asia. The blueprint will formulate a key set of strategic imperatives, with supporting actions.
The challenge of dengue is a collective one. We trust that by collaborating widely with a broad range of stakeholders, this blueprint will be adopted by all stakeholders who will then prioritise the actions that will deliver on the strategic imperatives.
By generating well-informed, focused and co-ordinated actions across the region, we hope to have a significant impact on dengue in Asia.
ADVA’s Mission:
1) Translate the science of dengue vaccination into clinical insights and recommendations to policy makers, healthcare workers and the general public.
2) Make practical recommendations for the design and implementation of dengue management programs.
An Evolving Mission
At its inception, ADVA, in both its title and focus stood for Asia Dengue Vaccination Advocacy. This has evolved to take on a broader remit in not only representing the Voice of Dengue in Asia, but also committing itself to Action.
This shift of focus to voice and action underpins the evolved definition of ADVA: Asia Dengue Voice and Action.
Asia Dengue Voice and Action
With input from government, public health entities, academia, the clinical community, consumer health organisations and industry bodies, ADVA has taken up the challenge of consulting and developing a regional blueprint for dengue management.
This blueprint will provide a cohesive, central and actionable point of view on dengue management across Asia. The blueprint will formulate a key set of strategic imperatives, with supporting actions.
The challenge of dengue is a collective one. We trust that by collaborating widely with a broad range of stakeholders, this blueprint will be adopted by all stakeholders who will then prioritise the actions that will deliver on the strategic imperatives.
By generating well-informed, focused and co-ordinated actions across the region, we hope to have a significant impact on dengue in Asia.